title: Decreased levels of homoarginine and asymmetric dimethylarginine in children with type 1 diabetes: associations with cardiovascular risk factors but no effect by atorvastin.
abstract: OBJECTIVE
  To investigate homoarginine and asymmetric dimethylarginine (ADMA) in controls compared to children with type 1 diabetes (T1D) and if homoarginine and ADMA are affected by atorvastatin.
  
  
  METHODS
  Homoarginine and ADMA levels of 28 T1D patients were compared to levels of 41 controls. In T1D patients, homoarginine and ADMA were determined at baseline, 1 year, and 2 years at daily 10 mg atorvastatin or placebo within a double-blind study.
  
  
  RESULTS
  At baseline, both homoarginine and ADMA were lower (p<0.001) in T1D patients compared to controls. In T1D patients, homoarginine and ADMA were not influenced by atorvastatin. Inverse correlations between homoarginine and HbA1c (p<0.001) and between ADMA and systolic blood pressure (p=0.005) and pulse pressure (p=0.003) were shown.
  
  
  CONCLUSIONS
  Homoarginine and ADMA levels are decreased and associated with cardiovascular risk factors in children with T1D without being affected by atorvastatin.
authors.forename: Andreas
authors.initials: A
authors.lastname: Krebs
authors.forename: Jürgen
authors.initials: J
authors.lastname: Doerfer
authors.forename: Sarah Catherina
authors.initials: SC
authors.lastname: Grünert
authors.forename: Jan
authors.initials: J
authors.lastname: Wöhrl
authors.forename: Bernhard
authors.initials: B
authors.lastname: Stier
authors.forename: Arno
authors.initials: A
authors.lastname: Schmidt-Trucksäss
authors.forename: Kai
authors.initials: K
authors.lastname: Lichte
authors.forename: Karl
authors.initials: K
authors.lastname: Winkler
authors.forename: Jürgen
authors.initials: J
authors.lastname: Grulich-Henn
authors.forename: Martin
authors.initials: M
authors.lastname: Holder
authors.forename: Karl Otfried
authors.initials: KO
authors.lastname: Schwab
mesh_terms: D000293:Adolescent; D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood; D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000517:prevention & control; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000378:metabolism; D006538:Heptanoic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D006709:Homoarginine / Q000097:blood*; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D010865:Pilot Projects; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use*; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D001120:Arginine; D000069059:Atorvastatin; D006442:Glycated Hemoglobin; D006538:Heptanoic Acids; D006709:Homoarginine; D008055:Lipids; D011758:Pyrroles; C517652:hemoglobin A1c protein, human; C018524:N,N-dimethylarginine